Arthur Leibowitz Acquires 5,000 Shares of Organogenesis (NASDAQ:ORGO) Stock

Organogenesis (NASDAQ:ORGO) Director Arthur Leibowitz acquired 5,000 shares of the stock in a transaction dated Monday, March 9th. The stock was acquired at an average cost of $2.68 per share, with a total value of $13,400.00. Following the transaction, the director directly owned 291,014 shares in the company, valued at approximately $779,917.52. This represents a 1.75% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Organogenesis Stock Down 1.1%

Shares of ORGO stock opened at $2.68 on Thursday. The stock’s fifty day moving average price is $3.79 and its 200 day moving average price is $4.48. Organogenesis has a 1-year low of $2.61 and a 1-year high of $7.08. The company has a market cap of $344.76 million, a price-to-earnings ratio of 33.50 and a beta of 1.43. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.62 and a quick ratio of 3.32.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.10. The company had revenue of $225.61 million during the quarter, compared to analysts’ expectations of $172.68 million. Organogenesis had a return on equity of 21.41% and a net margin of 5.32%. On average, research analysts expect that Organogenesis will post -0.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ORGO. Quarry LP purchased a new position in shares of Organogenesis in the third quarter worth about $25,000. State of Alaska Department of Revenue purchased a new stake in Organogenesis in the third quarter valued at approximately $25,000. Flagship Harbor Advisors LLC purchased a new stake in Organogenesis in the fourth quarter valued at approximately $34,000. Federated Hermes Inc. increased its holdings in Organogenesis by 52.8% in the 4th quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock worth $44,000 after buying an additional 2,953 shares during the period. Finally, Mercer Global Advisors Inc. ADV acquired a new position in Organogenesis in the 4th quarter worth approximately $57,000. 49.57% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ORGO has been the subject of several research analyst reports. Wall Street Zen raised shares of Organogenesis from a “hold” rating to a “buy” rating in a research report on Sunday. BTIG Research dropped their target price on shares of Organogenesis from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, February 27th. Finally, Weiss Ratings upgraded shares of Organogenesis from a “sell (d+)” rating to a “hold (c)” rating in a research note on Friday, February 27th. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Organogenesis has an average rating of “Moderate Buy” and an average target price of $8.50.

Organogenesis Company Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.